Shanghai Henlius Biotech, Inc. Class H

As of December 31, 2025, Shanghai Henlius Biotech, Inc. Class H carries a market capitalization of 31.01B, placing it among publicly traded companies globally. Its enterprise value stands at 34.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Henlius Biotech, Inc. Class H's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Shanghai Henlius Biotech, Inc. Class H has 543.49M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Shanghai Henlius Biotech, Inc. Class H maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Shanghai Henlius Biotech, Inc. Class H's stock has declined approximately 26.51% over the past 52 weeks. The 50-day moving average sits at 61.16, while the 200-day moving average is 65.10.

As of December 31, 2025, Shanghai Henlius Biotech, Inc. Class H holds 859.38M in cash and equivalents against 4.00B in total debt, resulting in a net debt position of 2.97B. Total book value stands at 4.41B, with working capital of -1.62B providing operational flexibility.